Arkadios Wealth Advisors’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Arkadios Wealth Advisors’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-500	Closed	-$12K	–	1916
2021 Q3	$12K	Hold	500	–	–	﹤0.01%	1401
2021 Q2	$17K	Buy	500 +200	+67%	+$7.81K	﹤0.01%	1366
2021 Q1	$12K	Hold	300	–	–	﹤0.01%	1143
2020 Q4	$12K	Buy	300 +150	+100%	+$7.39K	﹤0.01%	918
2020 Q3	$9.44K	Buy	+150	New	+$9.53K	﹤0.01%	758
2020 Q2	–	Sell	-75	Closed	-$3.83K	–	1181
2020 Q1	$3.83K	Hold	75	–	–	﹤0.01%	836
2019 Q4	$5.38K	Buy	+75	New	+$4.44K	﹤0.01%	693

Other funds holding GBT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Arkadios Wealth Advisors's GBT Position: Q4 2021 in Review

Arkadios Wealth Advisors sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2021, closing a stake of 500 shares — an estimated $12K sold.

Arkadios Wealth Advisors first reported a position in GBT in Q4 2019 and held it in 7 quarters. The position peaked at $17K in Q2 2021. 206 funds tracked by Wall St. Rank hold GBT as of Q4 2021.

Arkadios Wealth Advisors reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2021 after selling out during the quarter.
Arkadios Wealth Advisors sold 500 Global Blood Therapeutics, Inc. shares in Q4 2021, an estimated $12K.
Arkadios Wealth Advisors first reported a position in Global Blood Therapeutics, Inc. in Q4 2019 and held it in 7 quarters.
Arkadios Wealth Advisors's Global Blood Therapeutics, Inc. position peaked at $17K in Q2 2021.
206 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2021.

Based on Arkadios Wealth Advisors's 13F filing for Q4 2021, filed 3 Feb 2022.